Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 6/20 | 0.33 |
| ▸ | GHSR | Q92847 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | GRPR | P30550 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CALCR | P30988 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745528 | 0.93 | SLC18A2 (0.34) | SLC18A2F2APLNR | |
| SCHEMBL15744730 | 0.89 | APLNR (0.36) | SLC18A2APLNRGRPR | |
| SCHEMBL15745484 | 0.86 | CRHR1 (0.35) | SLC18A2GHSRF2APLNRGRPR | |
| SCHEMBL15744674 | 0.84 | CRHR1 (0.34) | SLC18A2GHSRF2APLNRGRPR | |
| SCHEMBL19084167 | 0.78 | APLNR (0.34) | SLC18A2GHSRF2APLNRGRPR | |
| SCHEMBL15745527 | 0.76 | APLNR (0.37) | SLC18A2GHSRAPLNR | |
| SCHEMBL26404165 | 0.76 | SLC18A2 (0.33) | SLC18A2 | |
| SCHEMBL15744685 | 0.74 | APLNR (0.36) | SLC18A2GHSRAPLNR | |
| SCHEMBL26404291 | 0.73 | SLC18A2 (0.34) | SLC18A2APLNR | |
| SCHEMBL26554013 | 0.70 | HTR1A (0.43) | SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | BAKARE OLADAPO (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | EML4, MCL1, ERAP2 | SLC18A2 1893/4885GHSR 3922/4885F2 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.